Phase II study of denileukin diftitox (ONTAK) for relapsed/refractory T-cell non-Hodgkin's lymphoma

被引：0
|
作者：
Dang, NH
Pro, B
Fredrick, HR
Samaniego, F
Jones, D
Rodriguez, M
Goy, A
Roaguera, J
Walker, PL
Younes, A
Neelapu, S
Kwak, L
Fayad, L
机构：
[1] Nevada Canc Inst, Las Vegas, NV USA
[2] MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3350
引用
收藏
页码：936A / 936A
页数：1
相关论文
共 50 条
  • [31] A phase II study of Xcellerated T cells™ in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (NHL).
    Bartlett, NL
    Gribben, JC
    Boccia, RV
    Milder, MS
    Aboulafia, DM
    Castro, J
    Flinn, I
    Hayes-Lattin, B
    Kaplan, L
    Lin, T
    Lucas, JB
    Maloney, DG
    McLaughlin, P
    McSweeney, PA
    Mohrbacher, A
    Redfern, C
    Steis, R
    Stephenson, JJ
    Strair, R
    Berenson, RJ
    Frohlich, MW
    BLOOD, 2004, 104 (11) : 244B - 244B
  • [32] Denileukin diftitox for the treatment of cutaneous T-cell lymphoma
    Kaminetzky, David
    Hymes, Kenneth B.
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (04): : 717 - 724
  • [33] Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-Cell non-Hodgkin's lymphoma
    Goy, A
    Younes, A
    McLaughlin, P
    Pro, B
    Romaguera, JE
    Hagemeister, F
    Fayad, L
    Dang, NH
    Samaniego, F
    Wang, M
    Broglio, K
    Samuels, B
    Gilles, F
    Sarris, AH
    Hart, S
    Trehu, E
    Schenkein, D
    Cabanillas, F
    Rodriguez, AM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) : 667 - 675
  • [34] A phase II study of denileukin diftitox (ONTAK) in patients with fludarabine refractory B-cell chronic lymphocytic leukemia.
    Lilly, M
    Kuriakose, P
    Turturro, F
    Berdeja, J
    Kerr, R
    Surendranathan, A
    Black, J
    Frankel, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 597S - 597S
  • [35] Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma
    S M Ansell
    H Tang
    P J Kurtin
    P A Koenig
    G S Nowakowski
    D A Nikcevich
    G D Nelson
    Z Yang
    D M Grote
    S C Ziesmer
    P T Silberstein
    C Erlichman
    T E Witzig
    Leukemia, 2012, 26 : 1046 - 1052
  • [36] Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma
    Ansell, S. M.
    Tang, H.
    Kurtin, P. J.
    Koenig, P. A.
    Nowakowski, G. S.
    Nikcevich, D. A.
    Nelson, G. D.
    Yang, Z.
    Grote, D. M.
    Ziesmer, S. C.
    Silberstein, P. T.
    Erlichman, C.
    Witzig, T. E.
    LEUKEMIA, 2012, 26 (05) : 1046 - 1052
  • [37] Phase II study of denileukin diftitox for previously treated low grade non-Hodgkin's lymphoma: E1497 final report.
    Eklund, JW
    Weller, E
    Kuzel, TM
    Foss, F
    Gascoyne, R
    Abramson, N
    Schwerkoske, JF
    Horning, S
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 605S - 605S
  • [38] De novo maintenance therapy with denileukin diftitox (Ontak®) in a patient with peripheral T-cell lymphoma is associated with prolonged remission
    Wong, Bryan Y.
    Ma, Yupo
    Fitzwilson, Robert
    Dang, Nam H.
    AMERICAN JOURNAL OF HEMATOLOGY, 2008, 83 (07) : 596 - 598
  • [39] Cutaneous γ-δ T-cell lymphoma treated with radiation and denileukin diftitox
    Vidulich, Kelley
    Duvic, Madeleine
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 58 (02) : AB102 - AB102
  • [40] Cutaneous γ/δ T-cell lymphoma treated with radiation and denileukin diftitox
    Vidulich, Kelley
    Jones, Dan
    Duvic, Madeleine
    CLINICAL LYMPHOMA & MYELOMA, 2008, 8 (01): : 55 - 58
12345